ALSO NOTED: Genta inks licensing deal on oncology program; Abbott, et al, target Tarceva gene test; Gilead submits marketing ap

> Genta has entered into an exclusive worldwide licensing agreement with Daiichi Sankyo for the development and commercialization of tesetaxel
(formerly known as DJ-927), a late Phase II oncology therapy. Release

> Millipore has inked a deal with Solabia to market materials used in manufacturing biologics. Release

> Abbott Laboratories' molecular diagnostics unit has joined with Genentech, OSI Pharmaceuticals and Roche to develop a gene test for Tarceva. Release

> Gilead Sciences has submitted a Marketing Authorization Application for marketing approval of aztreonam lysine 75 mg powder for nebuliser solution (aztreonam lysine) in the European Union. Release 

> Hovione has purchased 75 percent of Hisyn Pharmaceutical, a Chinese plant that manufactures drug substances. Story

> Novartis will use biomarker detection technology developed by Singulex for its drug development work. Report

> Shareholders have approved the sale of Pharmion to Celgene. Release

This week's most popular story: Pfizer snaps up Serenex in buyout. Report

And Finally... Genetic mutations involving insulin-like growth factor explain why short women live longer. Report

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.